PMID- 26084476
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20191113
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
VI  - 12
IP  - 3
DP  - 2016
TI  - A Systematic Review on Effect of Canagliflozin in Special Population.
PG  - 211-22
AB  - Canagliflozin is a competitive, reversible, highly selective SGLT2 inhibitor and 
      available in 100mg and 300mg as oral tablet form. Owing to this, it induced 
      glucosuria and cause changes in glucose homeostasis without affecting insulin. 
      This review addressed the efficacy and safety of canagliflozin in a specialized 
      patients such as chronic kidney disease (stage III CKD), high risk cardiovascular 
      patient and elderly population. Canagliflozin has reduced HbA1c in all the 
      specialized population, albeit reduction is less as compared to the normal 
      cohort. Additionally, canagliflozin causes reduction in body weight as well as in 
      blood pressure. It was very well tolerated and did not produce significant 
      adverse events compared to standard care (placebo) except genital mycotic 
      infection due to glucosuria. In cardio vascular safety analysis, canagliflozin 
      might be associated with increased incidence of major adverse cardiovascular plus 
      (MACE plus) events in the initial period, which is of concern in a high- risk 
      cardiovascular cohort. In patients with type 2 diabetes mellitus (T2 DM) and 
      stage III CKD cohort, canagliflozin was well tolerated without much affecting 
      eGFR and should be initiated with 100mg. Canagliflozin showed good safety profile 
      in elderly population with T2DM without significantly affecting overall bone 
      mineral density and bone resorption.
FAU - Patel, Sanket
AU  - Patel S
AD  - Department of Clinical Pharmacy, Ramanbhai Patel College of Pharmacy, Charotar 
      University of Science & Technology (CHARUSAT), CHARUSAT Campus, Changa - 388 421, 
      Gujarat, India. sankspatel86@yahoo.in.
FAU - Gohel, Kalpesh
AU  - Gohel K
FAU - Patel, Bharat Gordhanbhai
AU  - Patel BG
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United Arab Emirates
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
RN  - 0 (Hypoglycemic Agents)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Canagliflozin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology
MH  - Diabetic Angiopathies/drug therapy/epidemiology
MH  - Diabetic Nephropathies/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Renal Insufficiency, Chronic/drug therapy/epidemiology
MH  - Risk Factors
EDAT- 2015/06/19 06:00
MHDA- 2017/03/04 06:00
CRDT- 2015/06/19 06:00
PHST- 2015/04/15 00:00 [received]
PHST- 2015/05/22 00:00 [revised]
PHST- 2015/06/18 00:00 [accepted]
PHST- 2015/06/19 06:00 [entrez]
PHST- 2015/06/19 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
AID - CDR-EPUB-68131 [pii]
AID - 10.2174/1573399811666150618143948 [doi]
PST - ppublish
SO  - Curr Diabetes Rev. 2016;12(3):211-22. doi: 10.2174/1573399811666150618143948.